InMed announces ‘positive’ results from in vivo preclinical Alzheimer’s study

InMed Pharmaceuticals (INM) announces “positive” results from a long-term in vivo preclinical Alzheimer’s Disease study. In the study, INM-901 demonstrated a reduction in several plasma and brain markers of neuroinflammation, a recognized contributor to Alzheimer’s disease development and progression, the company reported. Dr. Eric Hsu, InMed’s SVP of Preclinical R&D, commented, “We are highly encouraged by the data from our long-term preclinical study of INM-901. Overall, our data showed a reduction of several neuroinflammation markers in an amyloid-induced Alzheimer’s disease model, suggesting that INM-901 may lower neuroinflammation. The ability of INM-901 to actively reduce inflammation is an exciting development, as neuroinflammation has emerged as a promising new drug target beyond existing AD treatments focused primarily on removing amyloid beta plaques and tau protein tangles. Over the last decade, the medical community has witnessed remarkable progress in understanding the pathology of Alzheimer’s disease; it is a multidimensional disease influenced by several factors that impact its progression and degenerative nature in human cognition. InMed’s earlier data suggested that INM-901 may address multiple pathological factors, making it a very promising drug candidate.”